SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves quarterly results and call dominate discussion: revenue beat expectations, guidance was raised and backlog expanded, while bulls see customer prepayments and contract-backed financing as easing funding concerns. Others argue heavy capital spending, debt and interest costs remain unresolved, fueling debate over the muted, volatile share-price reaction despite the strong report.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlists Q3 results and outlook are driving attention, with traders focused on improved profitability and recurring licensing revenue from its Samsung and Micron agreements, alongside growth plans for its memory products. Many are bullish, while others point to lower sequential product sales and the lack of concrete SK Hynix or Nasdaq updates; a further Hynix license remains speculation based on managements remarks.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigettis quarterly results missed revenue and adjusted-loss expectations, driving concern about weak commercial traction, ongoing cash burn, and a valuation that bears say is disconnected from current sales. Bulls counter that progress on its quantum systems and government support justify a longer-term view, leaving debate over technical milestones versus near-term business execution.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors Q3 call renewed focus on the FDAs pending Deramiocel decision, with management saying the application is in final review and the company is preparing for a potential launch. Many traders interpreted the CEOs confidence and comments about possible label scope as bullish signals, while others stressed that approval remains uncertain given the prior advisory-panel vote and unresolved FDA questions.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia shares are under pressure as a board investigation into CEO Jensen Huangs relationship with an executive reportedly linked to China-bound chip shipments raises governance, export-control and national-security concerns; the allegations remain unresolved. Traders are split between buying the dip on confidence in Nvidias AI business and worrying about Huangs future, regulatory fallout or further damaging disclosures.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costcos declared special dividend and renewed share-buyback authorization are driving attention, with many traders welcoming the shareholder return. Others argue the stock remains richly valued and note that a dividend does not create free value for shareholders.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius quarterly results are driving attention: revenue growth, expanding gross margins and raised full-year revenue guidance were offset by an EPS miss and weaker-than-expected EBITDA outlook, followed by a sharp selloff. Bulls view the decline as an overreaction to the small EPS miss, while others cite profitability and cash-burn concerns as reasons for caution.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. The firm offers annealing and gate-model quantum computing technologies. It provides professional services that assist customers in identifying and implementing quantum computing applications and selling quantum computer systems to customers. The company was founded by Eric Ladizinsky in 1999 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Waves Q3 earnings have sparked a selloff, with traders divided over revenue growth and a sizable backlog versus softer bookings, ongoing losses, and uncertainty about converting orders into revenue. Some see the pullback as an opportunity based on commercial progress, while skeptics argue the valuation remains difficult to justify.

Petróleo Brasileiro SA engages in oil and gas exploration, production, and distribution activities. It operates through the following segments: Exploration and Production; Refining, Transportation, and Marketing; and Gas and Low Carbon Energies. The Exploration and Production segment covers the activities of exploration, development, and production of crude oil, natural gas liquid, and natural gas, for the primary purpose of supplying its domestic refineries. The Refining, Transportation, and Marketing segment refers to refining, logistics, transport, and trading of crude oil and oil products activities as well as exports of ethanol. The Gas and Low Carbon Energies represents the activities of logistic and trading of natural gas and electricity, transportation and trading of liquefied natural gas, generation and electricity by means of thermoelectric power plants, as well as holding interests in transporters and distributors of natural gas. The company was founded on October 3, 1953 and is headquartered in Rio de Janeiro, Brazil.

Petroleo Brasileiro S.A. Petrobras - ADR

Petroleo Brasileiro

Petrobras Q3 results and earnings positioning are the main focus: traders point to record oil and diesel production and strong year-over-year performance, but also weigh quarter-over-quarter profit declines, softer Brent prices and one-time costs. The community is divided between optimism about operations and shareholder payouts and caution reflected in bearish put activity and questions about the share-price reaction.

Pepe (PEPE) is a cryptocurrency launched in 2023and operates on the Ethereum platform. Pepe has a current supply of 413,772,350,095,630.40630647. The last known price of Pepe is 0.00000541 USD and is up 5.91 over the last 24 hours. It is currently trading on 729 active market(s) with $746,473,881.04 traded over the last 24 hours. More information can be found at https://www.pepe.vip/.

Pepe

PEPE is drawing attention for volatile swings and periods of relative strength against a weak broader crypto market. Traders are cheering rebounds and talking up accumulation or a breakout, while skeptics warn that rallies have repeatedly faded and the token remains choppy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade

Bank of America upgrades Pharvaris to Buy with a new price target, citing reduced clinical risk for deucrictibant in hereditary angioedema despite market competition.read more...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers

Pharvaris (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion.
CalciMedica (NASDAQ:CALC) shares roseread more...

PHVS Stock Rises 10% in a Month: What Is Driving the Rally?

Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease

Equity

Pharvaris said on Tuesday its once-daily experimental pill cut monthly swelling attacks by 83% versus a dummy treatment in a late-stage study of hereditary angioedema patients. 


These 2 Biotech Stocks Hit Record Highs Today – What’s Driving The Rallies?

Roivant Sciences reported positive Phase 2 results for its experimental lung disease drug, Mosliciguat, while Pharvaris’ oral therapy met the main goal of a Phase 3 study of preventive treatment for hereditary angioedema.

Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday

U.S. stocks fell Tuesday, but Roivant surged 16% on positive PH-ILD trial data. Pharvaris, Solaris, IonQ and quantum stocks also posted strong gains.read more...

Why Is Pharvaris Stock Soaring Tuesday?

Pharvaris (PHVS) stock surges 17% on positive Phase 3 HAE trial data. Deucrictibant XR reduced monthly attacks up to 87%.read more...

Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet

The consensus price target hints at a 43% upside potential for Pharvaris (PHVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy

Does Pharvaris N.V. (PHVS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade

The mean of analysts' price targets for Pharvaris (PHVS) points to a 36.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.

Pharvaris NV

Bearish Sentiment

<ul class="summary-bullets"><li>BioCryst’s Orladeyo is approved to prevent HAE attacks.&nbsp;</li><li>Orladeyo sales have continued to grow, and the company is guiding for $625 million to $645 million in revenue from the drug this year.</li><li>BioCryst CEO Charlie Gayer said last month that the company wants to buy rare-disease medicines after Orladeyo's success.</li></ul><p>Shares of BioCryst Pharmaceuticals (BCRX) fell sharply on Tuesday after a competitor reported strong late-stage results in hereditary angioedema, the rare swelling disorder that underpins BioCryst’s main product.</p><p>BCRX fell 9% on Tuesday and clocked its worst day since late February. &nbsp;</p><h2 class="st-heading-2">A Rival Pill Raises The Bar</h2><p>The pressure came from Pharvaris (PHVS), which said its once-daily experimental pill cut monthly swelling attacks by 83% compared with a dummy treatment in a late-stage study. In the two most common forms of the disease, attacks fell by 87%. The medicine was generally well tolerated, and Pharvaris plans to seek approval in the first half of 2027. PHVS shares jumped 7% in regular trading and another 3% after-hours.</p><p>That market is the same one served by BioCryst’s Orladeyo, an approved once-daily capsule used to prevent attacks. Investors marked down Orladeyo on the risk of a stronger oral rival after 2027.</p><h2 class="st-heading-2">Orladeyo Market</h2><p>Orladeyo sales have continued to grow, and the company is guiding for $625 million to $645 million from the drug this year. A pellet version for young children has begun shipping after an earlier manufacturing delay. The drug has generated more than $2 billion in revenue since U.S. approval in 2020. BioCryst is also developing a second hereditary angioedema medicine, navenibart, with late-stage data still expected in 2027.</p><p>BioCryst CEO Charlie Gayer <a href="https://stocktwits.com/news-articles/markets/equity/bio-crysts-orladeyo-built-the-cash-pile-ceo-gayer-wants-to-buy-the-next-asset/cZYAopbRJrb">said</a> last month that the company wants to buy rare-disease medicines after Orladeyo's success. Gayer has said the next products should come from outside deals, not its own lab. Larger drugmakers have been chasing bigger assets. BioCryst is positioning itself as a buyer in the rare-disease gap they leave behind.</p><h2 class="st-heading-2">How Did BCRX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around BCRX rose from ‘bearish’ to ‘neutral’ over the past 24 hours, while message volume jumped from ‘low’ to ‘high’ levels.</p><p>A Stocktwits user dismissed Tuesday's selloff, noting that the company already has a real commercial product. “I’m really not worried.. it will go up sooner than later.. market trying to get rid of the weak hands,” they said.</p><p><stembedurl>https://stocktwits.com/Ray52baltimore/message/663832998</stembedurl></p><p>Another user opined that no one will switch out of Orladeyo even if Pharvaris’s drug gets approved. It also noted that PHVS is valued higher than BCRX despite having no approved products.</p><p><stembedurl>https://stocktwits.com/SCCT2FL/message/663813354</stembedurl></p><p><a href="https://stocktwits.com/symbol/BCRX">BCRX stock</a> has gained 16% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/dal-stock-drops-jefferies-sees-possible-snag-to-in-cabin-experience-owing-to-spcx-vsat-spectrum-fight/cZtE95BRJy5">DAL Stock Drops: Jefferies Sees Possible Snag To In-Cabin Experience Owing To SPCX-VSAT Spectrum Fight</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

CANADA - 2025/10/14: In this photo illustration, the BioCryst Pharmaceuticals (Bio Cryst) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Pharvaris said on Tuesday its once-daily experimental pill cut monthly swelling attacks by 83% versus a dummy treatment in a late-stage study of hereditary angioedema patients. 

Biocryst Pharmaceuticals Inc.

Yes, by year-end

Yes, but not this year

No, he stays as CEO

He steps down on his own

Do you think Jensen Huang will be removed as Nvidia’s ($NVDA) CEO?

Stocktwits

Do you think Jensen Huang will be removed as Nvidia’s (

Current Price	$33.99
Prev Close	$34.47
Open	$34.10
Dividend Yield	0.00%
50-Day Moving Average	$33.34
Beta	0.74
Avg. Volume	673,219.67
PE Ratio	-11.30

52-Week High	$43.25
52-Week Low	$22.41
Market Capitalization	$2.42B
EPS (Annual)	-$3.35
Price to Book	7.04
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

PHVS Fundamentals